{"analyses":[{"ciLowerLimit":"0.057","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.109","estimateComment":"Hazard ratio was based on an unstratified Cox proportional hazard regression model and treatment as a factor in the model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.383","pValueComment":"P-value comparing duration of CR in low blast AML between treatment groups is based on unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.420","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"10.2","value":"10.2"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"44.0","value":"12.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Disease responses for low-blast AML is based on revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0\\*10\\^9/L and plt of \\>=100\\*10\\^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (\\<1.0\\*10\\^9/L)/TTP (\\<100\\*10\\^9/L).","dispersionType":"Full Range","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a Baseline and at least 1 postbaseline disease assessment. Data is reported for responders with low blast AML having complete remission.","reportingStatus":"POSTED","timeFrame":"From date of randomization until CR (up to approximately 5 years)","title":"Duration of Complete Remission (CR) in Low-blast AML","type":"SECONDARY","unitOfMeasure":"months"}